Prostate Cancer Resource Guide Provides Comprehensive Info

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 9
Volume 6
Issue 9

BALTIMORE, Md-The American Foundation for Urologic Disease (AFUD) has developed and published a comprehensive resource guide for prostate cancer patients, their families and friends, and health care professionals. The publication contains detailed information about prostate cancer, as well as compilations of organizations, publications, and other resources related to the disease.

BALTIMORE, Md—The American Foundation for Urologic Disease (AFUD) hasdeveloped and published a comprehensive resourceguide for prostate cancer patients, their families and friends, andhealth care professionals. The publication contains detailed informationabout prostate cancer, as well as compilations of organizations, publications,and other resources related to the disease.

“As a survivor of prostate cancer, I understand how vital it is to haveinformation and resources,” says Hovey S. Dabney, AFUD Board Chairman.“When my cancer was diagnosed four years ago, my family, my health careteam, and I earnestly sought out current, accurate information. The Foundationhas designed this publication as a tool that will provide information andlead people to credible, authoritative resources about prostate cancer.”

AFUD President Jay Gillenwater, MD, of the University of Virginia HealthScience Center, says that the resource guide “will fill a critical informationvoid for patients, their families, and health care providers that shouldhelp improve the treatment and management of prostate cancer.”

The content of the resource guide begins with a chapter on “TreatmentChoices for Localized Prostate Cancer,” which is the reproduction of apatient education publication produced by the AFUD’s Prostate Health Council.Included in this chapter is a detailed definition of prostate cancer, explanationof disease stages, a detailed description of treatment options for localizedprostate cancer, and a glossary of prostate cancer terms.

Also included in the guide are tips from survivors; questions that patientsshould ask their health care providers; information on insurance coverageissues; home health care advice; nutrition information; a compilation ofsupport and advocacy organizations; background on FDA and NCI resourcesfor prostate cancer patients, including information on NCI-designated comprehensivecancer centers; and background on American Cancer Society programs aimedat prostate cancer patients and a list of state chapters, including addressesand phone numbers.

The 10-year-old AFUD is a nonprofit, patient-based organization dedicatedto the prevention and cure of urologic disease through the expansion ofresearch, education, awareness, and advocacy.

How to Order

Copies of the Prostate Cancer Resource Guide are available at $5 eachfrom the AFUD, P.O. Box 630605, Baltimore, MD 21263-0605; phone: 410-468-1800;or fax: 410-468-1808. Quantity orders should be arranged by phone or fax.The 1997 edition of the guide has been made possible through an educationalgrant from Hoechst Marion Roussel.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content